ENTERA BIO LTD (ENTX) Stock Price, Forecast & Analysis
USA - NASDAQ:ENTX - IL0011429839 - Common Stock
ENTX Key Statistics, Chart & Performance
The current stock price of ENTX is 3.04 USD. In the past month the price increased by 40.09%. In the past year, price increased by 76.74%.
ENTX Latest News, Press Relases and Analysis
ENTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 382.94B | ||
| AMGN | AMGEN INC | 14.63 | 172.20B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.02 | 106.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.31 | 68.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 852.08 | 56.96B | ||
| ARGX | ARGENX SE - ADR | 62.07 | 51.25B | ||
| INSM | INSMED INC | N/A | 39.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.19 | 35.30B | ||
| NTRA | NATERA INC | N/A | 27.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.86B | ||
| BIIB | BIOGEN INC | 9.17 | 22.49B |
Related stock screener links
About ENTX
Company Profile
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Company Info
ENTERA BIO LTD
Hadassah / Jerusalem Bio, Park, 5th Floor
JERUSALEM 9112002 IL
CEO: Spiros Jamas
Employees: 19
Phone: 97225327151
ENTERA BIO LTD / ENTX FAQ
What does ENTX do?
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
What is the current price of ENTX stock?
The current stock price of ENTX is 3.04 USD. The price increased by 8.57% in the last trading session.
Does ENTERA BIO LTD pay dividends?
ENTX does not pay a dividend.
What is the ChartMill rating of ENTERA BIO LTD stock?
ENTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of ENTX stock?
ENTERA BIO LTD (ENTX) operates in the Health Care sector and the Biotechnology industry.
What is the outstanding short interest for ENTERA BIO LTD?
The outstanding short interest for ENTERA BIO LTD (ENTX) is 0.28% of its float.
ENTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ENTX. When comparing the yearly performance of all stocks, ENTX is one of the better performing stocks in the market, outperforming 94.96% of all stocks.
ENTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ENTX. ENTX has a great financial health rating, but its profitability evaluates not so good.
ENTX Financial Highlights
Over the last trailing twelve months ENTX reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS increased by 46.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.91% | ||
| ROE | -61.44% | ||
| Debt/Equity | 0 |
ENTX Forecast & Estimates
7 analysts have analysed ENTX and the average price target is 10.2 USD. This implies a price increase of 235.53% is expected in the next year compared to the current price of 3.04.
For the next year, analysts expect an EPS growth of -30.56% and a revenue growth -69.78% for ENTX